Welcome to our dedicated page for Serina Therapeutics news (Ticker: SER), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Serina Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Serina Therapeutics's position in the market.
Serina Therapeutics (NYSE American: SER) announced that its management will participate in the BTIG Virtual Biotechnology Conference, held July 28-29, 2026, and will host virtual one-on-one investor meetings on Wednesday, July 29, 2026, arranged through BTIG representatives.
The company highlights its proprietary POZ Platform, a poly(2-oxazoline)-based polymer technology designed to optimize drug loading and controlled release for subcutaneous delivery, including a non-exclusive license agreement with Pfizer for use in lipid nanoparticle formulations. Serina also features SER-252, an investigational POZ-apomorphine therapy aiming to provide continuous dopaminergic stimulation in Parkinson’s disease.
Serina Therapeutics (NYSE American: SER) reported completion of enrollment and dosing of all eight patients in Cohort 1 of its ongoing Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease, ahead of prior guidance to finish by the end of the third quarter of 2026.
The randomized, double-blind, placebo-controlled study includes single-ascending-dose (five cohorts of eight, n=40) and multiple-ascending-dose parts (up to three cohorts of sixteen, n=48) to assess safety, tolerability and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures such as MDS-UPDRS motor scores. An independent Safety Monitoring Committee will now conduct a blinded review of Cohort 1 data to inform the next dose-escalation step. Trial sites are in the United States and Australia, with plans to add locations in South Korea and Taiwan.
Serina Therapeutics (NYSE American: SER) appointed biotech and pharma executive Farrell Simon, Pharm.D., to its Board of Directors, effective immediately, and named him to the Audit and Compensation Committees. Simon is Chief Commercial Officer at Trevi Therapeutics, where he leads commercial strategy, lifecycle management, pre-commercial planning, and business development, and has supported financings totaling more than $400 million from investors including Frazier, Vivo, Venrock and Viking. He previously spent a decade at Pfizer in senior commercial and strategic roles and holds a Pharm.D. and MBA in Finance from the University of Florida.
Serina also outlined the design of SER-252-1b, a randomized, double-blind, placebo-controlled Phase 1b study in adults with Parkinson’s disease and motor fluctuations, assessing single- and multiple-ascending subcutaneous doses of SER-252 versus placebo (up to 88 patients total). The trial will evaluate safety, tolerability and pharmacokinetics, with exploratory efficacy endpoints such as MDS-UPDRS motor scores, and is being run in the US and Australia with planned expansion to South Korea and Taiwan. The company highlighted its POZ Platform, based on poly(2-oxazoline) polymers designed to improve drug loading and release profiles for well-understood drugs with challenging pharmacokinetics, and referenced a non-exclusive license agreement allowing Pfizer to use its POZ polymer technology in lipid nanoparticle drug delivery.
Serina Therapeutics (NYSE American: SER) reported completion of sentinel dosing in Cohort 1 of its Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. An independent Safety Monitoring Committee recommended continued dosing, and additional patients are now being dosed in the US and Australia.
Serina now expects to finish Cohort 1 enrollment and dosing ahead of prior guidance of the end of the third quarter of 2026, subject to ongoing trial execution.
Serina Therapeutics (NYSE American: SER) reported Q1 2026 results and business updates. Operating expenses were $6.3 million and net loss was $6.9 million, or $(0.58) per share. Cash and cash equivalents totaled $24.5 million at March 31, 2026.
The Phase 1b registrational study of SER-252 in advanced Parkinson’s disease is underway, with Cohort 1 enrollment and dosing expected to complete by Q3 2026 and SAD TFL data targeted for the first half of 2027.
Serina closed a $21.2 million private placement in March and April 2026, and received an additional $5.2 million of gross proceeds in April 2026.
Serina Therapeutics (NYSE American: SER) will present at the 5th LNP Formulation & Process Development Summit on April 7, 2026 in Boston.
Presentation titled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform" will show that Serina’s POZ-lipid failed to elicit an antibody response in a vaccine-format rat study and previews a polymer‑lipid designed to bind diverse oligonucleotide payloads. Serina is also advancing POZ replacements for ionizable lipids to address LNP safety and versatility concerns.
Serina Therapeutics (NYSE American: SER) said NYSE American accepted its plan for continued listing compliance and granted a cure period through July 9, 2027. The company previously reported $1.6 million in stockholders' equity and multi-year losses. Serina will remain listed and face quarterly monitoring while it works to regain conformity; failure to comply could trigger suspension and delisting.
Serina Therapeutics (NYSE American: SER) reported full-year 2025 results and business highlights on March 25, 2026. Key items: FDA cleared an IND for SER-252 and the company dosed the first patient in a Phase 1b registrational trial for advanced Parkinson's disease. Serina secured financing, receiving $16.0M gross to date from a private placement and has raised $12.9M gross under an ATM program.
2025 operating expenses were $24.2M and net loss was $19.4M; cash totaled $3.1M at year-end.
Serina Therapeutics (NYSE American: SER) announced that CEO Steve Ledger will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026 at 11:30 a.m. PST.
A live webcast is available to registered attendees and an archived replay will be accessible on-demand for 90 days following the event.
Serina Therapeutics (NYSE:SER) secured a private placement to raise $15 million in a first tranche, with a second tranche available for up to an additional $15 million, for total proceeds of up to $30 million. The financing includes 50% warrant coverage and potential additional proceeds of up to $33.3 million from warrant exercises, and is expected to extend runway into 2H 2027. Proceeds will support the ongoing single-ascending dose registrational arm of SER-252 under a 505(b)(2) NDA pathway; initial patient dosing has begun and topline SAD results target 1H 2027.